SHIJIAZHUANG, China, Oct. 26, 2022 /PRNewswire/ -- CHEXPO Macau 2022 was officially opened on October 20, 2022. As one of the top 10 TCM enterprises in China, Yiling Pharmaceutical exhibited a number of its patented TCM and health products during the expo. As an international and frontier city of the Guangdong-Hong Kong-Macau Greater Bay Area, Macau becomes a good place for TCM international communication.
As China's first national-level consumer expo and the largest such kind in the Asia-pacific region, the 2nd China International Consumer Products...
SHIJIAZHUANG, China, May 12, 2022 /PRNewswire/ -- Yiling Pharmaceutical disclosed Wednesday that it had received the medicine approval document for Lianhua Qingwen Capsules from the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria. The Product Category is Herbal and Nutraceuticals.
SHIJIAZHUANG, China, April 30, 2022 /PRNewswire/ -- Yiling Pharmaceutical released its 2021 Annual Report Friday and disclosed the main development statistics. According to the report, its annual revenue reached USD 1.53 billion, an increase of 15.19% from last year, besides, net profit attributable to equity holders reached USD 203.75 million, achieving a 10.27% growth YoY.
BEIJING, Dec. 22, 2021 /PRNewswire/ -- According to Yiling Pharmaceutical's notice on Thursday (UTC+8), the Depression-resolving and Restlessness-relieving Capsules have been approved for marketing via the obtained Drug Registration Certificate issued by China's National Medical Products Administration (NMPA). The Company owns the full intellectual property rights of the drug.
Yiling's Generic Lamotrigine Receives Approval in the U.S.
Yiling Pharmaceutical's Paroxetine Hydrochloride Receives Approvals in US
SHIJIAZHUANG, China, Oct. 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical released the three-quarter report on the evening of October 28. In the first three quarters, the operating income of the company reached CNY 8.112 billion, up 25.81% year on year; the net profit attributable to shareholders of the listed company hit CNY 1.224 billion, up 20.43% from the previous year, surpassing that of last year as a whole; the weighted average return on equity was 13.40%, up 1.22 percentage points over the same period last year.
Yiling Pharmaceutical recently announced that its newly-developed drug Yishen Yangxin Anshen Tablet had been granted official drug certificate by China's National Medical Products Administration (NMPA).